POSEIDON PHARMACEUTICALS A/S: Financial statements 2013
CVR: 26133130
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
POSEIDON PHARMACEUTICALS A/S (CVR 26133130) has filed annual accounts for 2013. In 2013, the company reported a net result of DKK 140,000 compared with DKK 194,000 the year before. Equity in the 2013 report amounted to DKK 63,680,000. The solvency ratio was 100%.
- Profit/Loss
- DKK 140,000
- Equity
- DKK 63,680,000
- Total Assets
- DKK 63,695,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2013 | - | - | 140 t. | 63.7 mio. | - |
| 2012 | - | - | 194 t. | 63.5 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of November 29, 2013, Christian Dilling Elkjær Lundgren has joined the board of directors of POSEIDON PHARMACEUTICALS A/S.
As of November 29, 2013, Allan Andersen is registered as chairman of POSEIDON PHARMACEUTICALS A/S.
As of November 29, 2013, René Schneider has stepped down as chairman of POSEIDON PHARMACEUTICALS A/S.
As of April 16, 2013, René Schneider is registered as chairman of POSEIDON PHARMACEUTICALS A/S.
As of April 16, 2013, Jeppe Jensen has stepped down as chairman of POSEIDON PHARMACEUTICALS A/S.
POSEIDON PHARMACEUTICALS A/S has published its annual report for 2012. The net result was DKK 194,000.
About POSEIDON PHARMACEUTICALS A/S
POSEIDON PHARMACEUTICALS A/S was a Danish company of the type Aktieselskab based in Hellerup, founded in 2001. The company has been dissolved on 3 January 2017. The company was registered under the industry Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named THORAX ApS and KR 957 ApS. The company has 0 employees (2004). In 2015, the company reported a net result of DKK 143,000 compared with DKK 142,000 the year before. Equity in the 2015 report amounted to DKK 63,965,000.